冈比亚农村地区肺炎球菌结合疫苗接种两剂与三剂方案影响的整群随机非劣效试验:PVS试验
PVS试验是在冈比亚农村开展的前瞻性整群随机非劣效现场试验,比较1+1方案(6周龄一剂、9月龄加强一剂)与标准3+0方案(6、10、14周龄三剂)的群体影响。主要终点为试验第4年2周至59月龄临床肺炎儿童鼻咽部疫苗型肺炎球菌携带的群体水平患病率。68个地理人群整群按1:1随机分配,干预实施4年,结果将为全球减少剂量PCV方案的决策提供依据。
要点
- PVS试验比较1+1与3+0肺炎球菌结合疫苗方案的群体非劣效性。
- 主要终点为第4年2周至59月龄临床肺炎儿童疫苗型携带的群体患病率。
- 68个整群按1:1随机分配,干预实施4年,所有常住婴儿符合入组条件。
核心结论
- PVS试验将评估从标准3+0方案转为1+1方案在肺炎球菌高传播环境中的效果,其结果将为全球减少剂量PCV方案的决策提供依据。
研究设计与样本
- PVS为前瞻性、整群随机、非劣效、真实世界现场试验,比较6周龄一剂加9月龄加强一剂的1+1方案与6、10、14周龄三剂的3+0方案。
- 68个地理人群整群按1:1随机分配至各方案,所有常住婴儿符合入组条件,干预实施4年。
- 参与者和现场工作人员未对分组设盲,实验室终点测量设盲。
主要发现
- 主要终点为试验第4年2周至59月龄临床肺炎儿童鼻咽部疫苗型肺炎球菌携带的群体水平患病率。
- 所有5岁以下常住儿童在11个卫生机构接受临床安全性终点的持续监测,包括侵袭性肺炎球菌病、影像学肺炎、临床肺炎和住院。
- 次要终点包括第2年和第4年鼻咽部疫苗型肺炎球菌携带的群体水平患病率,以及第4年6至12周龄未免疫婴儿的疫苗型携带患病率。
- 试验包含数学建模、卫生经济学和卫生系统研究部分。
关键数值与推荐
- 非劣效界值依据替代方案相对于标准方案的「可接受效果损失」确定。
- 分析将考虑整群内测量的潜在非独立性,比较两种方案的群体水平影响并在个体水平进行解释。
- 次要终点将为主要终点的解释提供实质性证据。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pneumococcal conjugate vaccines (PCV) effectively prevent pneumococcal disease but the global impact of pneumococcal vaccination is hampered by the cost of PCV. The relevance and feasibility of trials of reduced dose schedules is greatest in middle- and low-income countries, such as The Gambia, where PCV has been introduced with good disease control but where transmission of vaccine-type pneumococci persists. We are conducting a large cluster-randomised, non-inferiority, field trial of an alternative reduced dose schedule of PCV compared to the standard schedule, the PVS trial. METHODS: PVS is a prospective, cluster-randomised, non-inferiority, real-world field trial of an alternative schedule of one dose of PCV scheduled at age 6 weeks with a booster dose at age 9 months (i.e. the alternative '1 + 1' schedule) compared to the standard schedule of three primary doses scheduled at 6, 10, and 14 weeks of age (i.e. the standard '3 + 0' schedule). The intervention will be delivered for 4 years. The primary endpoint is the population-level prevalence of nasopharyngeal vaccine-type pneumococcal carriage in children aged 2 weeks to 59 months with clinical pneumonia in year 4 of the trial. Participants and field staff are not masked to group allocation while measurement of the laboratory endpoint will be masked. Sixty-eight geographic population clusters have been randomly allocated, in a 1:1 ratio, to each schedule and all resident infants are eligible for enrolment. All resident children less than 5 years of age are under continuous surveillance for clinical safety endpoints measured at 11 health facilities; invasive pneumococcal disease, radiological pneumonia, clinical pneumonia, and hospitalisations. Secondary endpoints include the population-level prevalence of nasopharyngeal vaccine-type pneumococcal carriage in years 2 and 4 and vaccine-type carriage prevalence in unimmunised infants aged 6-12 weeks in year 4. The trial includes components of mathematical modelling, health economics, and health systems research. DISCUSSION: Analysis will account for potential non-independence of measurements by cluster, comparing the population-level impact of the two schedules with interpretation at the individual level. The non-inferiority margin is informed by the 'acceptable loss of effect' of the alternative compared to the standard schedule. The secondary endpoints will provide substantial evidence to support the interpretation of the primary endpoint. PVS will evaluate the effect of transition from a standard 3+ 0 schedule to an alternative 1 + 1 schedule in a setting of high pneumococcal transmission. The results of PVS will inform global decision-making concerning the use of reduced-dose PCV schedules. TRIAL REGISTRATION: International Standard Randomised Controlled Trial Number 15056916 . Registered on 15 November 2018.
引用
- Mackenzie GA, Osei I, Salaudeen R, et al. A cluster-randomised, non-inferiority trial of the impact of a two-dose compared to three-dose schedule of pneumococcal conjugate vaccination in rural Gambia: the PVS trial. Trials. 2022. PMID: 35073989. doi:10.1186/s13063-021-05964-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。